Adjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasms
| dc.creator | Cecilia Bonolode Campos | |
| dc.creator | Gleidice Eunice Lavalle | |
| dc.creator | Lidianne Narducci Monteiro | |
| dc.creator | Gabriela Rafaela Arantes Pêgas | |
| dc.creator | Silvia Ligório Fialho | |
| dc.creator | Débora Balabram | |
| dc.creator | Geovanni Dantas Cassali | |
| dc.date.accessioned | 2023-08-09T20:00:03Z | |
| dc.date.accessioned | 2025-09-09T00:16:34Z | |
| dc.date.available | 2023-08-09T20:00:03Z | |
| dc.date.issued | 2018 | |
| dc.format.mimetype | ||
| dc.identifier.doi | https://doi.org/10.21873/invivo.11429 | |
| dc.identifier.issn | 1791-7549 | |
| dc.identifier.uri | https://hdl.handle.net/1843/57662 | |
| dc.language | eng | |
| dc.publisher | Universidade Federal de Minas Gerais | |
| dc.relation.ispartof | In Vivo | |
| dc.rights | Acesso Aberto | |
| dc.subject | Talidomida | |
| dc.subject | Glândulas Mamárias Animais | |
| dc.subject.other | Thalidomide | |
| dc.subject.other | Canine | |
| dc.subject.other | Mamary gland | |
| dc.subject.other | Metastasis | |
| dc.title | Adjuvant thalidomide and metronomic chemotherapy for the treatment of canine malignant mammary gland neoplasms | |
| dc.type | Artigo de periódico | |
| local.citation.epage | 1666 | |
| local.citation.issue | 6 | |
| local.citation.spage | 1659 | |
| local.citation.volume | 32 | |
| local.description.resumo | Background/Aim: The aim of the present study was to evaluate a multimodal approach for the treatment of canine malignant mammary gland neoplasms, including surgery, chemotherapy, thalidomide, and metronomic chemotherapy (MC). Materials and Methods: Fifty-eight female dogs were submitted to four different treatments: surgery; surgery with chemotherapy; surgery with chemotherapy and thalidomide; and surgery with chemotherapy and metronomic chemotherapy and overall survival was evaluated. Results: No statistical difference was found in the proliferative index and microvessel density of primary neoplasms and distant metastases following thalidomide treatment. Diffuse intense inflammatory infiltrate was predominant in primary tumors and diffuse moderate inflammatory infiltrate in metastatic lesions. No statistically significant difference was observed in median survival time (MST) between treatment groups when including all clinical stages (p=0.3177). However, animals diagnosed with distant metastasis treated with surgery and chemotherapy associated with thalidomide or MC presented longer MST when compared to animals treated only with surgery or surgery and chemotherapy (p<0.0001). Conclusion: The proposed multimodal therapy protocols including antiangiogenic and immunomodulatory therapies demonstrated a clinical benefit for patients in advanced clinical stages. | |
| local.publisher.country | Brasil | |
| local.publisher.department | ICB - DEPARTAMENTO DE PATOLOGIA | |
| local.publisher.initials | UFMG | |
| local.url.externa | https://iv.iiarjournals.org/content/32/6/1659.long |